

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

Welcome to MESSENGER at USPTO

The USPTO production files are current through:

18 JAN 1994 for U.S. Patent Text Data.

18 JAN 1994 for U.S. Current Classification data.

18 JAN 1994 for U.S. Patent Image Data.

* PLEASE USE 305-9000 FOR NEW TELEPHONE NUMBER *

DISCLAIMER:

Neither the United States Government, nor any agency thereof, nor any of their contractors, subcontractors or employees make any warranty, expressed or implied, including any warranty of marketability of fitness for a particular purpose; nor assumes any legal liability or responsibility for any party's use, or the results of such, of the data.

There is a new number to call for APS help: 305-9000.

The Help Desk staff at this number will handle all APS related questions. Current hours are 6:30 am to 9:00 pm Monday through Friday and 7:30 am to 5:00 pm Saturday.

HOURS TO ACCESS MESSENGER ARE 6:30 AM to 9:00 PM

MONDAY THRU FRIDAY AND 7:30 AM to 5:00 PM SATURDAY.

FILE 'USPAT' ENTERED AT 14:32:53 ON 21 JAN 94

W E L C O M E T O T H E

U. S. P A T E N T T E X T F I L E

=> s (antivenin or venom?) and (fab or ((f)(W)(ab))

UNMATCHED LEFT PARENTHESIS 'AND (FAB'

=> s (antivenin or venom?) and (fab or ((f)(W)(ab)))

4 ANTIVENIN

890 VENOM?

3238 FAB

524985 F

18918 AB

1075 (F)(W)(AB)

L1 80 (ANTIVENIN OR VENOM?) AND (FAB OR ((F)(W)(AB)))

=> t l1 cit 1-80

1. 5,279,956, Jan. 18, 1994, Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C; John H. Griffin, et al., 435/183; 424/85.8; 435/69.2, 70.21, 240.27; 436/536; 514/12; 530/300, 324, 326, 328, 381, 382, 383, 384, 388.25, 388.26, 389.3, 412 [IMAGE AVAILABLE]

2. 5,279,937, Jan. 18, 1994, Use of macroglobulins to improve the signal-to-background ratio in affinity binding assays; Gerald E. Rowe, 435/6, 7.92, 7.93, 23, 971; 436/538 [IMAGE AVAILABLE]

3. 5,278,144, Jan. 11, 1994, Antithrombosis agents; David Wolf, 514/12; 424/94.64; 435/69.1, 69.2, 69.6; 514/2, 8; 530/384, 395 [IMAGE AVAILABLE]
4. 5,278,064, Jan. 11, 1994, Amycolatopsis mediterranei strains useful to prepare A87689 compounds; Dennis R. Berry, et al., 435/252.1; 424/122; 435/195, 253.2, 253.5 [IMAGE AVAILABLE]
5. 5,273,885, Dec. 28, 1993, Conjugates of monophenyl thyroid analogs useful in assays; Jill M. Visor, et al., 435/7.93, 7.9, 975 [IMAGE AVAILABLE]
6. 5,270,170, Dec. 14, 1993, Peptide library and screening method; Peter J. Schatz, et al., 435/7.37, 252.33, 320.1; 935/11 [IMAGE AVAILABLE]
7. 5,260,427, Nov. 9, 1993, Nucleosidylphosphite-borane compounds and method of making the same; Bernard F. Spielvogel, et al., 536/17.1; 435/91.5; 558/72; 562/11 [IMAGE AVAILABLE]
8. 5,256,642, Oct. 26, 1993, Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof; Douglas T. Fearon, et al., 514/8; 424/94.63, 94.64; 435/215, 216; 514/2; 530/350 [IMAGE AVAILABLE]
9. 5,252,712, Oct. 12, 1993, Purified antibodies which specifically bind human abnormal prothrombin; Bruce E. Furie, et al., 530/389.3; 435/240.27; 530/388.25 [IMAGE AVAILABLE]
10. 5,246,968, Sep. 21, 1993, Glutamate receptor inhibitor; Terumi Nakajima, et al., 514/616; 564/153 [IMAGE AVAILABLE]
11. 5,242,945, Sep. 7, 1993, Tetronic and thiotetronic acid derivatives as phospholipase A.sub.2 inhibitors; Craig E. Caufield, et al., 514/473, 445, 826; 549/64, 65, 313, 314, 316, 317 [IMAGE AVAILABLE]
12. 5,242,810, Sep. 7, 1993, Bifunctional inhibitors of thrombin and platelet activation; John M. Maraganore, et al., 435/69.2, 69.6, 69.7, 172.3, 214, 252.3, 252.33, 320.1; 530/324, 856; 536/23.1, 23.4, 23.5; 930/250 [IMAGE AVAILABLE]
13. 5,229,516, Jul. 20, 1993, Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase; John H. Musser, et al., 546/172, 152, 174, 175, 176, 180 [IMAGE AVAILABLE]
14. 5,229,500, Jul. 20, 1993, Brain derived neurotrophic factor; Yves-Alain Barde, et al., 530/399; 424/88; 435/69.1; 530/350, 387.9, 389.2, 412, 413 [IMAGE AVAILABLE]
15. 5,227,469, Jul. 13, 1993, Platelet aggregation inhibitors from the leech; Robert A. Lazarus, et al., 530/324, 326 [IMAGE AVAILABLE]
16. 5,227,397, Jul. 13, 1993, Polyamines and polypeptides useful as antagonists of excitatory amino acid neuro-transmitters and/or as blockers of calcium channels; Nicholas A. Saccomano, et al., 514/419, 12; 548/495 [IMAGE AVAILABLE]
17. 5,225,571, Jul. 6, 1993, Substituted dihydroxy-bis-[5-hydroxy-2(5H)-furanone-4-yl]-alkanes as anti-inflammatory agents; Gary C. M. Lee, 549/222, 313 [IMAGE AVAILABLE]

19. 5,225,100, Jan. 12, 1973, Synthesis of novel binding agents; Robert E. Johnson, et al., 100/207, 201, 170.0, 200.0, 200/207.0 [CLASS ABSTRACTED];

20. 5,225,100, Jan. 12, 1973, Hydroxyethylmethacrylate; Robert E. Johnson, et al., 100/207, 201, 170.0, 200.0, 200/20 [CLASS ABSTRACTED];

21. 5,225,100, Jan. 12, 1973, Synthesis and polymerization of novel binding agents; Robert E. Johnson, et al., 100/207, 201, 170.0, 200.0, 200/207.0 [CLASS ABSTRACTED];

22. 5,225,170, May 11, 1973, Methods of binding; Robert E. Johnson, et al., 100/207, 201/210, 200.0, 200/207 [CLASS ABSTRACTED];

23. 5,225,100, Jan. 12, 1973, Synthesis and polymerization; Robert E. Johnson, et al., 100/207, 201/202, 100/202, 200/20.10 [CLASS ABSTRACTED];

24. 5,100,100, Mar. 20, 1963, Inhibition of bacterial polysaccharide production; Sumner Rubin, et al., 100/14, 10, 200/200, 207, 200 [CLASS ABSTRACTED];

25. 5,100,200, Mar. 20, 1963, Characterization of plantlet aggregation; Mark H. Gansberg, 100/7.21, 7.21, 100/200, 210 [CLASS ABSTRACTED];

26. 5,100,270, Mar. 2, 1963, Hybrid cytoplasm aggregation containing legend binding sites; Waldemar Linnhardt, et al., 100/177, 20.1, 20.7, 200/200, 210, 200/200 [CLASS ABSTRACTED];

27. 5,107,200, Feb. 10, 1963, Intersegmental peptides; Gary C. Lee, 100/12, 10, 14, 10, 200/204, 200, 200, 207, 200 [CLASS ABSTRACTED];

28. 5,105,300, Feb. 9, 1963, Synthetic heterocyclic polymers as substituent amino acid nucleoside-nucleotide analogues; Nicholas A. Saccubano, et al., 100/200, 200/104, 210 [CLASS ABSTRACTED];

29. 5,100,000, Jan. 10, 1963, Enzymic synthesis of nucleosides; Yves Alain Bado, et al., 100/20.51, 100/20.1, 20.0, 170.0, 200.1, 200/200, 210 [CLASS ABSTRACTED];

30. 5,175,270, Dec. 20, 1962, Nucleic acid interacting agents; Kenneth W. Baschongberger, et al., 100/10.7 [CLASS ABSTRACTED];

31. 5,171,004, Dec. 18, 1962, Di (5 hydroxy 2(EH) 2 one 4 ethyl)methyl alpha,omega dihalo dicarbox and N,N bis (5 hydroxy 2(EH) 2 one 4 ethyl)methyl alpha,omega dihalo dicarboxylic acid amides as anti-inflammatory agents; Gary C. W. Lee, 100/200, 210 [CLASS ABSTRACTED];

32. 5,171,750, Dec. 18, 1962, Substituted phenoxazines as specific inhibitors of acetylcholinesterase; Arnold Brown, et al., 100/111, 100/100 [CLASS ABSTRACTED];

33. 5,100,000, Dec. 9, 1962, Di (5 hydroxy 2(EH) 2 one 4 ethyl)methyl alpha,omega dihalo dicarbox and N,N bis (5 hydroxy 2(EH) 2 one 4 ethyl)methyl alpha,omega dihalo dicarboxylic acid amides as anti-inflammatory agents; Gary C. W. Lee, 100/200, 210 [CLASS ABSTRACTED];

50. 5,001,574, Jun. 4, 1991, 2-Amino phenylacetic acid derivatives; Amador A. Fallis, et al., 546/174, 175 [IMAGE AVAILABLE]

51. 5,013,338, May 7, 1991, Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers; Eiko Ohtsuka, et al., 536/25.1, 25.2, 25.3, 25.34, 26.7, 26.72, 26.8, 27.63, 27.81, 28.5, 28.53 [IMAGE AVAILABLE]

52. 5,001,656, Mar. 19, 1991, Preparation of monoclonal antibodies; Solomon H. Snyder, et al., 435/70.21, 172.2, 173.6, 240.27; 935/93 [IMAGE AVAILABLE]

53. 4,960,712, Oct. 2, 1990, System and method for complement pathway analysis; Argyrios N. Theofilopoulos, et al., 436/501; 436/965, 973; 436/907, 512, 536, 539, 543, 904, 921 [IMAGE AVAILABLE]

54. 4,946,788, Aug. 7, 1990, Purified immunoglobulin-related factor, novel monoclonal antibodies, hybridoma cell lines, processes and applications; Guy Delespessis, 530/338.23; 424/85.6; 435/7.5, 70.21, 172.2, 183, 240.27, 948, 964; 530/338.73, 391.3, 362, 366, 368; 935/95, 100, 102, 103, 104, 106, 107, 108, 110 [IMAGE AVAILABLE]

55. 4,939,240, Jul. 3, 1990, Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy; Tsann M. Chu, et al., 530/338.95; 424/1.1, 85.3, 85.91; 435/70.21, 183, 240.27; 530/391.3, 391.7, 308, 309; 935/104, 107 [IMAGE AVAILABLE]

56. 4,930,817, Nov. 14, 1989, O-functionalized derivatives of substituted isoquinolin-3-ols having cardiotonic and/or phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties; Ramesh M. Kanojia, et al., 514/309, 210, 235.2, 253; 544/128, 363; 546/141 [IMAGE AVAILABLE]

57. 4,876,190, Oct. 24, 1989, Peridinin-chlorophyll complex as fluorescent label; Dieter J. Recktenwald, 435/7.2, 7.21, 7.23, 7.24, 963; 436/513, 537, 546, 900; 530/802 [IMAGE AVAILABLE]

58. 4,867,973, Sep. 19, 1989, Antibody-therapeutic agent conjugates; John W. F. Coors, et al., 424/85.91, 85.3, 86, 87; 514/2, 6, 8; 530/338.7, 388.9, 391.9, 328, 364, 366; 930/10, 22 [IMAGE AVAILABLE]

61. 4,645,355, Jul. 15, 1985, Immunoregulation of lymph. induction, lymph. response and auto induction: Peter G. Hough, 435/7.4, 4, 7.8, 12, 15, 18, 22, 435/300 [IMAGE AVAILABLE]

62. 4,645,351, Jul. 15, 1985, Indirectly purification particles: John D. Sullivan, et al., 435/35.1, 100, 435/311 [IMAGE AVAILABLE]

63. 4,655,340, Sep. 11, 1985, Method for isolation of antigen specific immunoglobulin from lung tum, et al., 444/35.8, 341, 435/35.1, 350/355.1, 355.1, 414, 410, 350 [IMAGE AVAILABLE]

64. 4,774,345, Sep. 17, 1985, Simultaneous growth monitoring particles: Hans Eberhard, et al., 350/344, 345, 346, 350, 350/10, 100, 510.011 [IMAGE AVAILABLE]

65. 4,785,310, Sep. 3, 1985, Immunoregulatory means and methods used in human native pertussis and human chorionic pertussis determinations: David H. Smith, et al., 435/7.34, 7.13, 7.4, 15, 340, 435/35, 350, 340, 350, 341, 345, 345, 350/304, 304, 350.15, 350 [IMAGE AVAILABLE]

66. 4,784,433, Mar. 15, 1985, Simultaneous growth monitoring particles: Hans Eberhard, et al., 350/344, 444/35.34, 345/1, 11, 11, 350/350, 405, 405, 350, 350/10, 10, 100, 510.011 [IMAGE AVAILABLE]

67. 4,744,705, Dec. 11, 1987, 4 nitrogen substituted benzimidazole compounds having cardiotonic, phosphodiesterase inhibition and inhibitory properties and/or other regulating properties: Russell H. Hanson, et al., 344/305, 340/141 [IMAGE AVAILABLE]

68. 4,787,350, Nov. 17, 1987, Synthetic peptide based anti rabies compositions and methods: James W. Patrick, et al., 424/300, 330/10, 220 [IMAGE AVAILABLE]

69. 4,875,207, Jun. 23, 1987, Monoclonal antibody directed to human ganglioside GD.sub.2: Ralph A. Reisfeld, et al., 435/7.13, 424/35.8, 35.81: 435/7.82, 70.11, 172.2, 240.17, 340, 375: 435/510, 510, 540, 513: 530/387.5, 380.1, 380.85, 391.3, 390, 390, 390: 335/30, 35, 180, 187 [IMAGE AVAILABLE]

70. 4,872,044, Jun. 9, 1987, Murine monoclonal antibody combining site to human G3b receptor (CR1): Robert D. Schreiber, 435/301: 435/4, 7.21, 7.24, 7.25, 70.11, 172.2, 240.17, 310, 360, 375: 435/504, 500, 507, 512, 510, 530, 540, 540, 515, 521: 335/104, 110 [IMAGE AVAILABLE]

71. 4,871,950, Jun. 9, 1987, Antibody conjugates for the delivery of compounds to target sites: John D. Rodwell, et al., 424/35.01, 1.1, 35.8, 36, 37: 514/2, 6, 9: 530/389.6, 391.5, 391.9, 320, 364, 366 [IMAGE AVAILABLE]

72. 4,661,347, Apr. 28, 1987, Cytotoxic compositions: Hans J. Muller-Eberhard, et al., 424/35.01: 435/189: 530/388.85, 391.7, 391.9, 395, 402, 403, 404, 409 [IMAGE AVAILABLE]

73. 4,652,629, Mar. 24, 1987, Synthetic peptide-based anti-rabies compositions and methods: James W. Patrick, et al., 530/326, 327, 328, 329, 330, 403: 930/10, 220 [IMAGE AVAILABLE]

74. 4,642,284, Feb. 10, 1987, Method and system for detection of complement pathway activation: Neil Cooper, et al., 435/7.94, 4, 7.4, 28,

(Item 1 from file: 155)

04954594 83187594

Simplified preparation of rabbit Fab fragments.

Coulter A; Harris R

J Immunol Methods Apr 29 1983, 59 (2) p199-203, ISSN 0022-1759

Journal Code: IFE

Languages: ENGLISH

Document type: JOURNAL ARTICLE

JOURNAL ANNOUNCEMENT: 8308

Subfile: INDEX MEDICUS

Papain attached to solid-phase CH-Sepharose 4B was used to digest rabbit IgG. Protein A-Sepharose CL-4B was used to remove undigested IgG and Fc fragments. Pure Fab fragments free of IgG, Fc fragments and papain were readily obtained by this procedure with a yield of about 75%. Polyacrylamide gel electrophoresis of the Fab in the presence of sodium dodecyl sulphate gave a single band under both reducing and non-reducing conditions. The molecular weight of the Fab determined by sedimentation equilibrium was 49,200. Unlike the IgG, the Fab obtained did not form precipitin lines when used in immunoelectrophoresis.

Tags: Animal

Descriptors: *Immunoglobulins, Fab--Isolation and Purification--IP; Chromatography, Ion Exchange; Electrophoresis, Polyacrylamide Gel; IgG --Analysis--AN; Immunoenzyme Techniques; Immunoglobulins, Fab--Analysis--AN ; Mice; Molecular Weight; Neurotoxins--Immunology--IM; Rabbits; Snake Venoms--Immunology--IM

CAS Registry No.: 0 (Immunoglobulins, Fab); 0 (Neurotoxins); 0 (Snake Venoms)

6